An encapsulated bacteriophage formulation and a method for encapsulating bacteriophages and bacteriophage-related products in polymeric microcapsules is provided. Some embodiments of the method of producing the encapsulated bacteriophages involves a water-in-oil-in-water double emulsion.

Provided herein are methods and compositions for killing a target bacterium. Also disclosed are engineered bacteriophages.

Disclosed is preparation of a cocktail as a therapeutic agent for cow mastitis and use thereof. A compatibility of phages against the main pathogenic bacteria of cow mastitis is utilized in combination with a specific preparation method to prepare and obtain a therapeutic cocktail preparation. The therapeutic phage cocktail preparation for cow mastitis provided in the disclosure is easy to prepare, short in course of treatment and quick in effect. It has better therapeutic effect on both clinical cow mastitis and recessive mastitis than that of antibiotics and antimicrobial peptide and is expected to solve the problem of bacterial resistance in the treatment of cow mastitis, thereby reducing or getting rid of the troubles of diseases such as mastitis in cows, which is of potential development value in cow farming.

The present disclosure features compositions and methods for the treatment of bacterial infections, such as bacterial infections caused by bacterial cells residing within a host cell (e.g., a mammalian cell, e.g., immune cell, e.g., macrophage or dendritic cell). The compositions and methods include delivering antimicrobial agents to specifically target the intracellular compartment (endosome, phagosome, lysosome, or cytosol) in which the bacterial cell resides.

Provided herein are methods and compositions for killing a target bacterium. Also disclosed are engineered bacteriophages.

An object of the present invention is to provide a recombinant phage having high safety and excellent practicality and usefulness. Provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a bacteriophage genome in which a part of a virion constituent gene is deleted is stored in a head, and a method for preparing the same. In addition, provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a plasmid having a packaging site and encoding a target gene is stored in a head, and a method for preparing the same.

Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.

Disclosed herein are methods and systems for rapid diagnosis and treatment of biofilm-related infections in a subject having a medical implant. A reporter cocktail composition is disclosed herein and may be used to detect a microorganism of interest and determine the presence of an infection. A therapeutic cocktail composition is also disclosed herein and may be used to treat a subject diagnosed with a biofilm-related infection.

A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be “universal”; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1×10.sup.9 PFU/ml) for use in therapeutic applications.

Provided herein are methods and compositions for killing a target bacterium. Also disclosed are engineered bacteriophages.